Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity.

[1]  Zhijian J. Chen,et al.  cGAS in action: Expanding roles in immunity and inflammation , 2019, Science.

[2]  J. Bertin,et al.  Design of amidobenzimidazole STING receptor agonists with systemic activity , 2018, Nature.

[3]  R. Vance,et al.  Tumor‐Derived cGAMP Triggers a STING‐Mediated Interferon Response in Non‐tumor Cells to Activate the NK Cell Response , 2018, Immunity.

[4]  L. Galluzzi,et al.  Cytosolic DNA Sensing in Organismal Tumor Control. , 2018, Cancer Cell.

[5]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[6]  G. Barber,et al.  Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. , 2018, Cancer cell.

[7]  Zhijian J. Chen,et al.  The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer , 2018, The Journal of experimental medicine.

[8]  M. Fehlings,et al.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.

[9]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[10]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[11]  C. Figdor,et al.  Migrating into the Tumor: a Roadmap for T Cells. , 2017, Trends in cancer.

[12]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[13]  Martin A. M. Reijns,et al.  cGAS surveillance of micronuclei links genome instability to innate immunity , 2017, Nature.

[14]  C. Ager,et al.  Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity , 2017, Cancer Immunology Research.

[15]  Dennis E Discher,et al.  Mitotic progression following DNA damage enables pattern recognition within micronuclei , 2017, Nature.

[16]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[17]  J. Wolchok,et al.  Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells , 2017, Science Immunology.

[18]  Yuanyuan Ruan,et al.  Decreased expression of STING predicts poor prognosis in patients with gastric cancer , 2017, Scientific Reports.

[19]  Zhijian J. Chen,et al.  cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.

[20]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[21]  K. Ishii,et al.  DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity , 2017, The Journal of Immunology.

[22]  Hsi-Yuan Huang,et al.  DNA-Sensing and Nuclease Gene Expressions as Markers for Colorectal Cancer Progression , 2016, Oncology.

[23]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[24]  J. Massagué,et al.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer , 2016, Nature.

[25]  D. Munn,et al.  STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. , 2016, Cancer research.

[26]  Xiangshi Tan,et al.  Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.

[27]  G. Barber,et al.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. , 2016, Cell reports.

[28]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[29]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[30]  M. Okoniewski,et al.  Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. , 2015, Immunity.

[31]  K. Ishii,et al.  Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. , 2015, Cell reports.

[32]  A. Kröger,et al.  DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. , 2015, Immunity.

[33]  E. Janssen,et al.  STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells , 2014, The Journal of Immunology.

[34]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[35]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[36]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[37]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[38]  G. Barber,et al.  Inflammation-driven carcinogenesis is mediated through STING , 2014, Nature Communications.

[39]  Jonathan L. Schmid-Burgk,et al.  Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP , 2013, Nature.

[40]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[41]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[42]  Roger A. Jones,et al.  Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase , 2013, Cell.

[43]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA , 2013, Science.

[44]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[45]  M. van den Broek,et al.  Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation , 2012, The Journal of Immunology.

[46]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[47]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[48]  R. Weichselbaum,et al.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.

[49]  M. Faretta,et al.  Bacteria-Induced Gap Junctions in Tumors Favor Antigen Cross-Presentation and Antitumor Immunity , 2010, Science Translational Medicine.

[50]  G. Barber,et al.  STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity , 2009, Nature.

[51]  K. Rajewsky,et al.  Novel Reporter Mouse Reveals Constitutive and Inflammatory Expression of IFN-β In Vivo1 , 2009, The Journal of Immunology.

[52]  R. Locksley,et al.  Visualization of IFNβ production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo , 2008, Proceedings of the National Academy of Sciences.

[53]  G. Barber,et al.  STING an Endoplasmic Reticulum Adaptor that Facilitates Innate Immune Signaling , 2008, Nature.

[54]  R. Schreiber,et al.  Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function1 , 2007, The Journal of Immunology.

[55]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[56]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[57]  E. Jaffee,et al.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Lutfalla,et al.  Domains of interaction between alpha interferon and its receptor components. , 1994, Journal of molecular biology.

[59]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[60]  Holger Moch,et al.  Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. , 2018, Cancer research.

[61]  M. van den Broek,et al.  A Quantitative Pathology Approach to Analyze the Development of Human Cancer-Associated Tertiary Lymphoid Structures. , 2018, Methods in molecular biology.

[62]  Shelly A Bambina,et al.  Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. , 2016, Cancer research.

[63]  M. Fenech,et al.  Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. , 2011, Mutagenesis.

[64]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[65]  R. Medzhitov,et al.  Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. , 2006, Immunity.

[66]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.